Sonoma Pharmaceuticals (SNOA) Stock Statistics & Valuation Metrics

Sonoma Pharmaceuticals has a market cap or net worth of $8.79M. The enterprise value is $1.74M.

Sonoma Pharmaceuticals has 1,643,265 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sonoma Pharmaceuticals’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -44.68%.

The current PE Ratio of Sonoma Pharmaceuticals is ―. Sonoma Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Sonoma Pharmaceuticals had revenue of 14.29M and earned -3.46M in profits. Earnings per share was -2.79.

In the last 12 months, operating cash flow was -1.19M and capital expenditures -181.00K, giving a free cash flow of -1.37M billion.

Sonoma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Sonoma Pharmaceuticals upcoming earnings date is Nov 17, 2025, After Close (Confirmed).

Sonoma Pharmaceuticals as a current ratio of 3.09, with Debt / Equity ratio of 16.64%

In the past 12 months, Sonoma Pharmaceuticals has paid 550.00K in taxes.

Sonoma Pharmaceuticals EV to EBITDA ratio is 0.66, with an EV/FCF ratio of 14.00.

Sonoma Pharmaceuticals has $3.60M in cash and marketable securities with $675.00K in debt, giving a net cash position of -$2.93M billion.

Gross margin is 37.71%, with operating margin of -25.97%, and net profit margin of -24.20%.

The average price target for Sonoma Pharmaceuticals is $5.50, which is 11.43% higher than the current price. The consensus rating is Hold